Novartis AG (NVS)
| Market Cap | 190.64B |
| Revenue (ttm) | 49.92B |
| Net Income (ttm) | 15.25B |
| Shares Out | 1.96B |
| EPS (ttm) | 7.38 |
| PE Ratio | 22.35 |
| Forward PE | 13.25 |
| Dividend | $3.78 (3.88%) |
| Ex-Dividend Date | Mar 7, 2024 |
| Volume | 1,461,353 |
| Open | 97.76 |
| Previous Close | 99.06 |
| Day's Range | 97.44 - 98.22 |
| 52-Week Range | 92.19 - 108.78 |
| Beta | 0.48 |
| Analysts | Hold |
| Price Target | 115.00 (+18.02%) |
| Earnings Date | Apr 23, 2024 |
About NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $115.0, which is an increase of 18.02% from the latest price.
News
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies
Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem® (artemether-lum...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the tr...
Novartis CEO: Here's why we boosted our full-year guidance
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.
Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb
American depositary receipts (ADRs) of Novartis (NVS) rose in intraday trading Tuesday as the Swiss-based pharmaceutical firm reported better-than-expected first-quarter results and boosted its guidan...
Novartis CEO: Broadly Positive About Business Momentum
Novartis CEO Vas Narasimhan said the company saw a very good performance across both established medicines and recent drug launches. "While there was a small contribution from generics getting pushed ...
Novartis shares jump as drugmaker boosts outlook
Novartis shares rallied on Tuesday as the Swiss drugmaker raised its outlook for the year after seeing strong demand for heart and psoriasis drugs.
Shares of Novartis climb 4.8% on raised guidance, better-than-expected results
Shares of Swiss drugmaker Novartis climbed 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results.
Novartis Ups Guidance on Profit, Sales Growth
Novartis lifted its full-year guidance after first-quarter profit and sales rose and beat consensus expectations, boosted by strong sales of key drugs.
Novartis lifts FY guidance after Q1 results beat expectations
Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results.
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LR Q1 net sales grew +11% (cc 1 , +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entre...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Basel, April 17, 2024 – Novartis today announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® (ofatumumab) treatment for up to six y...
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1 IgAN is a heterogeneous, progressive, rare ki...
Arvinas inks over $1.0 billion deal with Novartis
Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 million ...
Novartis begins tender offer for MorphoSys
Novartis said on Thursday that its tender offer for MorphoSys has begun, with an offer price of 68 euros ($73.08) per share in cash, corresponding to a premium of 142% on the volume-weighted average p...
Novartis tender offer for MorphoSys AG commences
Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG ...
Novartis to cut 680 jobs in product development
Novartis is to cut up to 680 jobs in its development organisation, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday.
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
V- INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant L...
Novartis To Seek Label Expansion of Prostate Cancer Treatment After Successful Study
Shares of Novartis (NVS) climbed Thursday as the pharmaceutical firm announced it would seek approval for expanded use of its cancer treatment, Pluvicto.
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Basel, March 22, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended gr...
3 Top Stocks to Watch From the Best International Money Managers
#Morningstar #NovoNordisk #StockInvesting Managers of highly rated funds own these foreign stocks. Should you?
US appeals court revives Regeneron's antitrust lawsuit against Novartis
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders inclu...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Basel, March 5, 2024 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1693 shareho...
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Basel, March 4, 2024 – Novartis today presented new data that continue to support the clinical benefits of Zolgensma® (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of sp...
FANG, NVDA, CSCO, NVS: Stock Picks in the Current Market
Diamondback Energy (FANG) consistently posted some of the strongest operational and financial results among the independent producers, notes Victoria Bills. She discusses he stock picks which include ...